Asian Society of Gynecologic Oncology International Workshop 2018

Kong, Tae-Wook; Ryu, Hee Sug; Kim, Seung Cheol; Enomoto, Takayuki; Jin, Li; Kim, Kenneth H.; Shim, Seung‐Hyuk; Wang, Peng Hui; Therasakvichya, Suwanit; Kobayashi, Yusuke; Lee, Maria; Shi, Tingyan; Lee, Shin-Wha; Mikami, Mikio; Nagase, Satoru; Lim, Myong Cheol; Wang, Jianliu; Wilailak, Sarikapan; Kim, Sang Wun; Hong, Sook Hee; Tan, David S.P.; Mandai, Masaki; Chang, Suk-Joon; Huang, Ruby Yun‐Ju; Ushijima, Kimio; Lee, Jung‐Yun; Chen, Xiaojun; Ochiai, Kazunori; Lee, Taek Sang; Yang, Bingyi; Kalam, Farhana; Lv, Qiaoying; Ahmad, Mohd Faizal; Yaznil, Muhammad Rizki; Modi, Kanika Batra; Manopunya, Manatsawee; Jeong, Dae Hoon; Lertkhachonsuk, Arb Aroon; Chung, Hyun Hoon; Watari, Hidemichi; Jeon, Seob

doi:10.3802/jgo.2019.30.e39

Cited by 9 publications

(7 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in patients with any one intermediate risk factor, the additional benefit of chemoradiation could not be demonstrated in the STARS trial (Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer), although sequential chemoradiation was superior to radiation alone. Presently, GOG 263/KROG1008 is testing the role of chemoradiation 22. Unlike the treatment intensification strategies adopted in the intermediate risk group in the trials mentioned above, the CERVANTES trial (NCT 04989647) is testing the omission of radiation 23.…”

Section: Role Of Adjuvant Systemic Chemotherapy In the Postoperative ...mentioning

confidence: 99%

Postoperative adjuvant radiation for cervix cancer: reflections on the evidence and a peep into the future

Chopra

Ranjan

Mittal

2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Early stage cervical cancer, stages IB1–2 and IIA1, can be treated with (chemo)radiation and brachytherapy or radical hysterectomy with or without further adjuvant (chemo)radiation. In a carefully selected cohort for surgery, traditionally a small proportion of patients would need adjuvant (chemo)radiation so that the therapeutic ratio is maximized. However, advances in radiation technology, specifically intensity modulated radiotherapy, have led to a reduction in treatment related adverse events. Also, recent developments in risk stratification suggest using a lower threshold to offer adjuvant treatment to minimize pelvic relapse. These developments together present opportunities of not only re-examining the therapeutic ratio but also of further evolving postoperative risk stratification. This review article summarizes the current evidence on adjuvant treatment strategies and summarizes the key areas where research should be focused.

show abstract

Section: Role Of Adjuvant Systemic Chemotherapy In the Postoperative ...mentioning

confidence: 99%

Postoperative adjuvant radiation for cervix cancer: reflections on the evidence and a peep into the future

Chopra

Ranjan

Mittal

2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Minor variations of fertility-sparing treatment by other gynecologic oncology societies are primarily in regards to follow-up biopsy; the Japan Society of Gynecologic Oncology recommends endometrial biopsy at 3 months following progestin treatment [101], and the Korean Society of Gynecologic Oncology recommends endometrial biopsy at 3-6 month for fertilitysparing treatment of grade 1 endometrioid tumors confined to the endometrium [102]. In addition, the Gynecologic Oncology Branch of the Chinese Medical Association requires patients to be under the age of 40 and progesterone-receptor positive to be considered for fertility-sparing therapy [103]. • Patients who wish to conceive following a complete response should be advised to pursue pregnancy earlier and consider ART to improve success rates.…”

Section: Guidelines and Recommendationsmentioning

confidence: 99%

Fertility-sparing treatment in early endometrial cancer: current state and future strategies

et al. 2020

View full text Add to dashboard Cite

Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries. Most women are diagnosed postmenopausal, but 14–25% of patients are premenopausal and 5% are under 40 years of age. Established risk factors include age and hyperestrogenic status associated with nulliparity, obesity, and metabolic syndrome. Standard treatment for EC, which involves total hysterectomy and bilateral salpingo-oophorectomy, has excellent survival outcomes, particularly for low-grade endometrioid tumors. However, it leads to permanent loss of fertility among women who wish to preserve their reproductive potential. With current trends of reproductive-age women delaying childbearing, rising EC incidence rates, and a growing epidemic of obesity, particularly in developed countries, research on conservative non-surgical treatment approaches remains a top priority. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies. Randomized clinical trials in younger women and high-risk obese patients are currently underway. Here, we have presented a comprehensive review of the current literature on conservative, fertility-sparing approaches, defining the optimal candidates and evaluating tumor characteristics, reproductive and oncologic outcomes, and ongoing clinical trials. We have also summarized current guidelines and recommendations based on the published literature.

show abstract

“…The aim of this symposium was to maintain a good relationship among Asian countries to encourage international collaborations through clinical trials for gynecologic cancer. Prof. Tae-Wook Kong (Ajou University School of Medicine, Suwon, Republic of Korea) presented oncologic outcomes of minimally invasive radical hysterectomy after using parametrial invasion criteria on magnetic resonance imaging and vaginal colpotomy and concluded that the operation should be performed more cautiously, in optimal surgical candidates, to obtain en bloc resection without positive margin and tumor spillage, using vaginal colpotomy after CO 2 evacuation [7][8][9]. Prof. Kung-Liahng Wang (President of the Taiwanese Gynecologic Oncology Group) presented updates regarding the controversies of laparoscopic or robotic surgeries for cervical cancer, and discussed the disagreement in the literature regarding the effect of utilizing laparoscopic or robotic surgery versus traditional laparotomy regarding the risk of decreasing survival among patients with cervical cancers [10,11].…”

Section: Jsgo Annual Meeting 2019mentioning

confidence: 99%

“…He presented the recent activities of KGOG, such as the ongoing joint research with Japanese Gynecologic Oncology Group (JGOG), including KGOG3011/GCIG/JGOG3017, KGOG3026/JGOG3019/GOTIC-001, and KGOG3035/JGOG3020 [34], as well as the KGOG-JGOG Young Doctors' Meeting and the regular exchange program of young medical scientists between KGOG and JGOG. Prof. Seung Cheol Kim (President of the Korean Society of Gynecologic Oncology [KSGO]) presented a history of KSGO and the Journal of Gynecologic Oncology ( JGO ), especially the recent relationship with JSGO [567].…”

mentioning

confidence: 99%

The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO)

et al. 2019

Self Cite

View full text Add to dashboard Cite

The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO) was held from July 4th to 6th, 2019, at the Tokki Messe International Convention Center in Niigata, Japan, with Prof. Takayuki Enomoto serving as the Congressional Chair (Fig. 1). The theme of this meeting was "Precision Medicine in Gynecologic Oncology: From Bench to Clinic" and there were two invited lectures, three special lectures, three symposiums, four workshops, three mini-workshops, five young-doctor's seminars, 117 oral presentations in 25 sessions, 513 poster presentations and an Asian Gynecologic Oncology Submit. A list of the invited and special lectures is shown in Table 1. More than 2,000 participants, from 8 countries/regions

show abstract

Asian Society of Gynecologic Oncology International Workshop 2018

Cited by 9 publications

References 100 publications

Postoperative adjuvant radiation for cervix cancer: reflections on the evidence and a peep into the future

Postoperative adjuvant radiation for cervix cancer: reflections on the evidence and a peep into the future

Fertility-sparing treatment in early endometrial cancer: current state and future strategies

The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO)

Contact Info

Product

Resources

About